Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

BACKGROUND: Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed and refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further therapies will be. Moreover,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Carreau, Nicole A., Pail, Orrin, Armand, Philippe, Merryman, Reid, Advani, Ranjana H., Spinner, Michael A., Herrera, Alex, Chen, Robert, Tomassetti, Sarah, Ramchandren, Radhakrishnan, Hamid, Muhammad S., Assouline, Sarit, Santiago, Raoul, Wagner‐Johnston, Nina, Paul, Suman, Svoboda, Jakub, Bair, Steven, Barta, Stefan, Liu, Yang, Nathan, Sunita, Karmali, Reem, Burkart, Madelyn, Torka, Pallawi, David, Kevin, Wei, Catherine, Lansigan, Frederick, Emery, Lukas, Persky, Daniel, Smith, Sonali, Godfrey, James, Chavez, Julio, Xia, Yuhe, Troxel, Andrea B., Diefenbach, Catherine
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2020
Aiheet:
Hematologic Malignancies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543382/
https://ncbi.nlm.nih.gov/pubmed/32720734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0167
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia